Oncolytic Viruses: a new immunotherapeutic approach for breast cancer treatment?
Cette étude passe en revue les données pré-cliniques et cliniques concernant l'intérêt des virus oncolytiques dans le traitement du cancer du sein
Immunotherapy has revolutionized the oncology field during the last years, mainlywith the introduction of immune checkpoint inhibitors in the clinical routine. Despitethe recent approval of these drugs for the treatment of triple-negative breast cancer,most breast cancer patients cannot benefit from immunotherapy as most tumors are notconsidered immunoreactive. Therefore, new strategies must be developed to bring immunotherapycloser to breast cancer patients. The introduction of oncolytic viruses in the immuno-oncologyfield has shown promising results in cancer treatment, including breast cancer. However,a better understanding of their mechanisms of action, increase evidence of safetyand efficacy, and the implications of its use as a systemic therapy must be examinedin more depth. This review provides a summary of oncolytic virotherapy in the contextof breast cancer, both in the pre-clinical and clinical setting.